Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
Remestemcel-L's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for Remestemcel-L. Showing past 6 months and next 12 months · 11 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| Remestemcel-L | Mesoblast | Mesenchymal Stem Cell | Phase 3 | 0 | ||||
| Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil | Kumamoto University | — |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Acetazolamide Per os for Decompensation of Heart Failure | Samara State Medical University | — | Phase 4 | — | — | — | — | — |
| Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure | Evi Liliek Wulandari | — | Phase 4 | — | — | — | — | — |
| Colchicine in Patients With Heart Failure With Preserved Ejection Fraction and Inflammation | Dongying Zhang | — | Phase 4 | — | — | — | — | — |
| Effect of Oral sucRosomIal Iron on exerciSE Capacity and Quality of Life in Patients With Heart Failure | Raffaele De Caterina | — | Phase 4 | — | — | — | — | — |
| The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF | University Clinical Hospital Mostar | — | Phase 4 | — | — | — | — | — |
| Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II | Fazaia Ruth Pfau Medical College | — | Phase 4 | — | — | — | — | — |
| The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron Deficiency | China-Japan Friendship Hospital | — | Phase 4 | — | — | — | — | — |
| Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | — | Phase 4 | — | — | — | — | — |
| The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF) | Tomsk National Research Medical Center of the Russian Academy of Sciences | — | Phase 4 | — | — | — | — | — |
| Qishenyiqi for Ventricular Remodeling After Myocardial Infarction | Qilu Hospital of Shandong University | — | Phase 4 | — | — | — | — | — |
| Allograft Dysfunction in Heart Transplant | Paul Kim | — | Phase 4 | — | — | — | — | — |
| The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis | Nicholas Carlson | — | Phase 4 | — | — | — | — | — |
| Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device | Columbia University | — | Phase 4 | — | — | — | — | — |
| Vericiguat and Reverse Remodeling Indices in Heart Failure | University Medical Centre Ljubljana | — | Phase 4 | — | — | — | — | — |
| EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease | National Taiwan University Hospital | — | Phase 4 | — | — | — | — | — |
| Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease | National Taiwan University Hospital | — | Phase 4 | — | — | — | — | — |
| Metoprolol in Patients With HFrEF and COPD | Xiangya Hospital of Central South University | — | Phase 4 | — | — | — | — | — |
| A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record | Herlev and Gentofte Hospital | — | Phase 4 | — | — | — | — | — |
| Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure | AstraZeneca | — | Phase 4 | — | — | — | — | — |
| Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score | Boston Children's Hospital | — | Phase 3 | — | — | — | — | — |
| S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction | Shenzhen People's Hospital | — | Phase 3 | — | — | — | — | — |
| CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine | Niguarda Hospital | — | Phase 3 | — | — | — | — | — |
| A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients | Fundación para la Investigación del Hospital Clínico de Valencia | — | Phase 3 | — | — | — | — | — |
| The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction | John Paul II Hospital, Krakow | — | Phase 3 | — | — | — | — | — |
| The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | University Medical Center Groningen | — | Phase 3 | — | — | — | — | — |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | X4 Pharmaceuticals | — | Phase 3 | — | — | — | — | — |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Cytokinetics | — | Phase 3 | — | — | — | — | — |
| Outpatient Hypertonic Saline and Loop Diuretic Combination Therapy in Cardiorenal | University of Monastir | — | Phase 3 | — | — | — | — | — |
| Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure | Pharmacosmos A/S | — | Phase 3 | — | — | — | — | — |
| Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease | Alessandro Doria | — | Phase 3 | — | — | — | — | — |
| Dapagliflozin for Cardio-renal Protection After ICU Discharge | Assistance Publique - Hôpitaux de Paris | — | Phase 3 | — | — | — | — | — |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Eli Lilly and Company | — | Phase 3 | — | — | — | — | — |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | Boehringer Ingelheim | — | Phase 3 | — | — | — | — | — |
| Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction. | Tongji Hospital | — | Phase 3 | — | — | — | — | — |
| Communication During Hospitalization About Resuscitation Trial | University of Vermont | — | PHASE2/PHASE3 | — | — | — | — | — |
| Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure | Jens D Hove, MD,PHD | — | PHASE2/PHASE3 | — | — | — | — | — |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | CSL Behring | — | PHASE2/PHASE3 | — | — | — | — | — |
| Study to Assess Safety and Efficacy of Treating Symptomatic, Ischemic, Chronic Congestive Heart Failure Patients with an LVEF of ≤40% with Fresh, Uncultured, Autologous, Adipose-derived Regenerative Cells Isolated from Lipoaspirate. | Ralf Rothoerl | — | Phase 2 | — | — | — | — | — |
| Ertugliflozin in Chronic Heart Failure | Yale University | — | Phase 2 | — | — | — | — | — |
| Study of JK07 in Patients With Chronic Heart Failure | Salubris Biotherapeutics Inc | — | Phase 2 | — | — | — | — | — |
| Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction | Akros Pharma Inc. | — | Phase 2 | — | — | — | — | — |
| Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study | Maximo Agustin Schiavone | — | Phase 2 | — | — | — | — | — |
| Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation | University of Texas Southwestern Medical Center | — | Phase 2 | — | — | — | — | — |
| Endocalyx for Heart Failure | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | — | Phase 2 | — | — | — | — | — |
| Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure | Tasly Pharmaceutical Group Co., Ltd | — | Phase 2 | — | — | — | — | — |
| Swedish Cardiac And Renal Failure Study-1 | Karolinska Institutet | — | Phase 2 | — | — | — | — | — |
| Chronic Exogenous Ketosis in HFpEF | Duke University | — | Phase 2 | — | — | — | — | — |
| Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR) | Nantes University Hospital | — | Phase 2 | — | — | — | — | — |
| Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS) | University Medical Center Groningen | — | Phase 2 | — | — | — | — | — |